7, 2014 Nallamothu et al. February 25, 2014:722 45 ACC/AHA/SCAI/AMA-PCPI/NCQA Appendix B. Continued Peer Reviewer Representation Consultant Speaker s Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Bene t Expert Witness Frederick A. Masoudi Content Reviewerd ACC NCDR Science and Quality Oversight Committee Content ReviewerdAHA None None None None None None Laura Mauri Of cial ReviewerdAHA  Abbott  Cordis  Johnson & Johnson  Medtronic None None  Abbotty  Abiomedy  Boston Scienti cy  Bristol-Myers Squibby  Cordisy  Daiichi Sankyoy  Eli Lillyy  Johnson & Johnsony  Medtronicy  Sano -Aventisy  Harvard Clinical Research Institutey None None James K. Min Content Reviewerd ACC Appropriate Use Criteria Task Force None  GE Healthcare  TC3*  Phillips Healthcare*  Arineta* None None Manesh R. Patel Content Reviewerd ACC Appropriate Use Criteria Task Force None None None None None None Eric D. Peterson Of cial Reviewerd ACC/AHA Task Force on Performance Measures  Boehringer Ingelheim  Genentech  Janssen Pharmaceuticals  Johnson & Johnson  Merck None None  Eli Lillyy  Johnson & Johnsony  Janssen Pharmaceuticalsy  DCRIz None Sunil V. Rao Of cial ReviewerdSCAI  AstraZeneca  Bristol-Myers Squibb  Cordis  Daiichi Sankyo  Terumo Medical  The Medicines Company None None  Sano -Aventis  Abbott Vascular* None None Matthew T. Roe Content Reviewerd ACC NCDR Science and Quality Oversight Committee  KAI Pharmaceuticalsy  Daiichi Sankyoy  GlaxoSmithKline  Janssen Pharmaceuticalsy  Eli Lilly  Bristol-Myers Squibby  Sano -Aventisy None  AstraZenecay  Bristol-Myers Squibby  Eli Lillyy  Mercky  Roche Pharmaceuticalsy  Sano -Aventisy  AstraZeneca*  AstraZenecadlectures performed within DCRI None Frank Rybicki Content Reviewerd ACC/AHA/ACR/AMA- PCPI/NCQA Cardiac Imaging Writing Committee None None None  Bracco Diagnosticsy  Toshiba Medical Systemsy None None Leslee Shaw Content Reviewerd ACC Appropriate Use Criteria Task Force None None None  Bracco Diagnostics None None Marc Shelton Content Reviewerd ACC Board of Governors None None None None None None John Spertus Content Reviewerd ACC Appropriate Use Criteria Coronary Revascularization  Genentech  United Healthcare Sci- enti c Advisory Board  Amgen None None  Eli Lillyy  CV Outcomes* None Raymond F. Stainback Content Reviewerd ACC Appropriate Use Criteria Task Force None None None None None None Continued on the next page Nallamothu et al. 